BACKGROUND: Long-term survival after lung transplant is limited by the development of chronic and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome (BOS). While prior studies strongly implicate cellular rejection as a strong risk factor for BOS, less is known about the clinical significance of human leukocyte antigen (HLA) antibodies and donor HLA-specific antibodies in long-term outcomes. METHODS: A single-center cohort of 441 lung transplant recipients, spanning a 10-year period, was prospectively screened for HLA antibodies after transplant using flow cytometry-based methods. The prevalence of and predictors for HLA antibodies were determined. The impact of HLA antibodies on survival after transplant and the development of BOS were determined using Cox models. RESULTS: Of the 441 recipients, 139 (32%) had detectable antibodies to HLA. Of these 139, 54 (39%) developed antibodies specific to donor HLA. The detection of posttransplant HLA antibodies was associated with BOS (HR, 1.54; P=.04) and death (HR, 1.53; P=.02) in multivariable models. The detection of donor-specific HLA antibodies was associated with death (HR, 2.42; P<.0001). The detection of posttransplant HLA antibodies was associated with pretransplant HLA-antibody detection, platelet transfusions, and the development of BOS and cytomegalovirus pneumonitis. CONCLUSIONS: Approximately one-third of lung transplant recipients have detectable HLA antibodies, which are associated with a worse prognosis regarding graft function and patient survival.
BACKGROUND: Long-term survival after lung transplant is limited by the development of chronic and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome (BOS). While prior studies strongly implicate cellular rejection as a strong risk factor for BOS, less is known about the clinical significance of human leukocyte antigen (HLA) antibodies and donor HLA-specific antibodies in long-term outcomes. METHODS: A single-center cohort of 441 lung transplant recipients, spanning a 10-year period, was prospectively screened for HLA antibodies after transplant using flow cytometry-based methods. The prevalence of and predictors for HLA antibodies were determined. The impact of HLA antibodies on survival after transplant and the development of BOS were determined using Cox models. RESULTS: Of the 441 recipients, 139 (32%) had detectable antibodies to HLA. Of these 139, 54 (39%) developed antibodies specific to donor HLA. The detection of posttransplant HLA antibodies was associated with BOS (HR, 1.54; P=.04) and death (HR, 1.53; P=.02) in multivariable models. The detection of donor-specific HLA antibodies was associated with death (HR, 2.42; P<.0001). The detection of posttransplant HLA antibodies was associated with pretransplant HLA-antibody detection, platelet transfusions, and the development of BOS and cytomegalovirus pneumonitis. CONCLUSIONS: Approximately one-third of lung transplant recipients have detectable HLA antibodies, which are associated with a worse prognosis regarding graft function and patient survival.
Authors: C L Lau; S M Palmer; K E Posther; D N Howell; N L Reinsmoen; H T Massey; V F Tapson; J J Jaggers; T A D'Amico; R D Davis Journal: Ann Thorac Surg Date: 2000-05 Impact factor: 4.330
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Alin L Girnita; Kenneth R McCurry; Aldo T Iacono; Rene Duquesnoy; Timothy E Corcoran; Mohamed Awad; Kathy J Spichty; Samuel A Yousem; Gilbert Burckart; James H Dauber; Bartley P Griffith; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2004-10 Impact factor: 10.247
Authors: Cynthia M Magro; April Deng; Amy Pope-Harman; W James Waldman; A Bernard Collins; Patrick W Adams; Moira Kelsey; Patrick Ross Journal: Transplantation Date: 2002-11-15 Impact factor: 4.939
Authors: Cynthia M Magro; Dana Marshall Klinger; Patrick W Adams; Charles G Orosz; Amy L Pope-Harman; W James Waldman; Deborah Knight; Patrick Ross Journal: Am J Transplant Date: 2003-10 Impact factor: 8.086
Authors: Steven K Takemoto; Adriana Zeevi; Sandy Feng; Robert B Colvin; Stanley Jordan; Jon Kobashigawa; Jerzy Kupiec-Weglinski; Arthur Matas; Robert A Montgomery; Peter Nickerson; Jeffrey L Platt; Hamid Rabb; Richard Thistlethwaite; Dolly Tyan; Francis L Delmonico Journal: Am J Transplant Date: 2004-07 Impact factor: 8.086
Authors: Scott M Palmer; R Duane Davis; Denis Hadjiliadis; Marshall I Hertz; David N Howell; Fran E Ward; Kay Savik; Nancy L Reinsmoen Journal: Transplantation Date: 2002-09-27 Impact factor: 4.939
Authors: Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun Journal: Transpl Int Date: 2020-01 Impact factor: 3.782
Authors: Ariss DerHovanessian; Jamie L Todd; Alice Zhang; Ning Li; Aradhna Mayalall; C Ashley Finlen Copeland; Michael Shino; Elizabeth N Pavlisko; W Dean Wallace; Aric Gregson; David J Ross; Rajan Saggar; Joseph P Lynch; John Belperio; Laurie D Snyder; Scott M Palmer; S Sam Weigt Journal: Ann Am Thorac Soc Date: 2016-05
Authors: Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer Journal: Am J Respir Crit Care Med Date: 2014-01-15 Impact factor: 21.405
Authors: Patrick J Smith; James A Blumenthal; Benson M Hoffman; Sarah K Rivelli; Scott M Palmer; Robert D Davis; Joseph P Mathew Journal: Ann Am Thorac Soc Date: 2016-02